



1 AGCATCCTGA GTAATGAGTG GCCTGGGGCG GAGCAGGGGA GGTGGCCGGA GCCGTGTGGA CCAGGAGGAG CGCTTTCCAC AGGGCCTGTG GACGGGGGTG
TCGTAGGACT CATTACTAC CGGACCCGCG CTCGTCCGCT CCACCGGCCT CGGCACACCT GGTCTCCTC GCGAAAGTG TCCCGGACAC CTGCCCCAC
1 M S G L G R S R R S R R S R V D Q E E R F P Q G L W T G V
101 GCTATGAGT CCTGCCCCGA AGAGCAGTAC TGGGATCCTC TGCTGGGTAC CTGCATGTCC TGCAAAACCA TTGCAACCA TCAGAGCCAG CGCACCTGTG
CGATACTCTA GGACGGGGCT TCTCGTCATG ACCCTAGGAG ACGACCCATG GACGTACAGG ACGTTTGGT AAACGTTGGT AGTCTCGGTG GCGTGGACAC
30 A M R S C P E E Q Y W D P L L G T C M S C K T I C N H Q S Q R T C A
201 CAGCCTTCTG CAGGTCACTC AGCTGCCGCA AGGAGCAAGG CAAGTTCTAT GACCATCTCC TGAGGGACTG CATCAGCTGT GCCTCCATCT GTGGACAGCA
GTCCGAAGAC GTCCAGTGAG TCGACGGCGT TCCTCGTTCC GTTCAAGATA CTGGTAGAGG ACTCCCTGAC GTAGTCGACA CGGAGGTAGA CACCTGTCTG
64 A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G Q H
301 CCCTAAGCAA TGTGCATACT TCTGTGAGAA CAAGCTCAGG AGCCAGTGA ACCTTCCACC AGAGCTCAGG AGACAGCGGA GTGGAGAAGT TGAACAACAT
GGGATTCTGT ACACGTATGA AGACACTCTT GTTCGAGTCC TCGGTCACT TGGAAAGTGG TCTCGAGTCC TCTGTGCTT CACCTCTTCA ACTTTTGTTA
97 P K Q C A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N
401 TCAGACAACT CGGGAAGTA CCAAGGATTG GAGCACAGAG GCTCAGAAGC AAGTCCAGCT CTCCCGGGC TGAAGCTGAG TGCAGATCAG GTGGCCCTGG
AGTCTGTTGA GCCCTTCCAT GGTTCCTAAC CTCGTGCTC CGAGTCTTCG TTCAGGTGGA GAGGGCCCCG ACTTCGACTC ACGTCTAGTC CACCGGGACC
130 S D N S G R Y Q G L E H R G S E A S P A L P G L K L S A D Q V A L V
501 TCTACAGCAC GCTGGGGCTC TGCTGTGTG CCGTCTCTG CTGCTTCTG GTGGCGGTGG CCTGCTTCTT CAAGAAGAGG GGGATCCTT GCTCCTGCCA
AGATGTCTGT CGACCCCGAG ACGGACACAC GGCAGGAGAC GACGAAGGAC CACCGCCACC GGACGAAGGA GTTCTTCTCC CCCCTAGGGA CGAGGACGGT
164 Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q
601 GCCCGCTCA AGGCCCGTC AAAGTCCGGC CAAGTCTTCC CAGGATCAG CGATGGAAGC CGGAGGCCCT GTGAGCACAT CCCCCGAGCC AGTGGAGACC
CGGGCGGAGT TCCGGGGCAG TTTCAGGCGG GTTCAGAAGG GTCCTAGTGC GCTACCTTCG GCCGTCCGGA CACTCGTGA GGGGGCTCGG TCACCTCTGG
197 P R S R P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T
701 TGCAGCTTCT GCTTCCCTGA GTGCAGGGCG CCCACGCAGG AGAGCGCAGT CACGCCCTGG ACCCCCGACC CCACCTGTGC TGAAGGTGG GGGTGCCACA
ACGTCGAAGA CGAAGGACT CACGTCCCGC GGGTCCGTCC TCTCGGTCA GTGCGGACCC TGGGGCTGG GGTGAACACG ACCTTCCACC CCCACGGTGT
230 C S F C F P E C R A P T Q E S A V T P G T P D P T C A G R W G C H T
801 CCAGGACCAC AGTCTCTGAG CCTTGCCAC ACATCCCAGA CAGTGGCCTT GGCATTGTGT GTGTGCCCTG CCAGGAGGGG GGCCAGGTG CATAAATGGG
GGTCTGGTG TCAGGACGTC GGAACGGGTG TGTAGGTCT GTACCCGGA CCGTAACACA CACACGACG GGTCTCCCC CCGGGTCCAC GTATTACCC
264 R T T V L Q P C P H I P D S G L G I V C V P A Q E G G P G A O

FIG. 1A



901 GGTCAGGGAG GGAAAGGAGG AGGAGAGAG ATGGAGAGGA GGGAGAGAG AAAGAGAGGT GGGAGAGGG GAGAGAGATA TGAGGAGAGA GAGACAGAGG
CCAGTCCCTC CCTTCCCTCC TCCCTCTCTC TACCTCTCTC CCCCTCTCTC TTTCTCTCCA CCCCTCTCCC CTCTCTCTAT ACTCCTCTCT CTCTGTCTCC

1001 AGGCAGAAAG GGAGAGAAAC AGAGGAGACA GAGAGGGAGA GAGAGACAGA GGGAGAGAGA GACAGAGGG AAGAGAGGCA GAGAGGGAAA GAGGCAGAGA
TCCGTCTTC CCTCTTTG CTCTCTTG TCTCCTCTGT CTCTCCCTCT CTCTCTGTCT CCCTCTCTCT CTGTCTCCCC TTCTCTCCGT CTCTCCCTTT CTCCGTCTCT

1101 AGGAAAGAGA CAGGCAGAGA AGGAGAGAG TCCCTCTCTC GTCTCTCCCT GTCTCTCTCT CTCCCTCTCT CCGTCTCTCT GTCTCTCCCT CTCTCTCTAT
TCCTTTCTCT GTCCGTCTCT TCCCTCTCTC GTCTCTCTCT CTCTCCGTCT CTCTCTCTCT CCGTCTCTCT GTCTCTCCCT CTCTCTCTAT

1201 GAGCAGGAGG TCGGGGCACT CTGAGTCCCA GTTCCCAGTG CAGCTGTAGG TCGTCATCAC CTAACCCACAC GTGCAATAAA GTCCTCGTGC CTGCTGCTCA
CTCGTCTCC AGCCCGGTGA GACTCAGGT CAAGGGTCAC GTCGACATCC AGCAGTAGTG GATTGGTGTG CACGTTATTT CAGGAGCACC GACGACGAGT

1301 CAGCCCCCGA GAGCCCTCTC TCCTGGAGAA TAAACCTTT GGCAGCTGCC CTTCCTCAA AAAAATAA
GTCCGGGGCT CTCGGGAGG AGGACCTCTT ATTTGGAA CCGTCGACCG GAAGGAGTT TTTTTTTT

FIG. 1B



USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 3 of 29

1 AAGACTCAA CTTAGAAACT TGAATTAGAT GTGGTATTCA AATCCTTACG TGCCGCGAAG ACACAGACAG CCCCCGTAAG AACCCACGAA GCAGGCGAAG
TTCTGAGTTT GAATCTTTGA ACTTAATCTA CACCATAAGT TTAGGAATGC ACGGCGCTTC TGTGTCTGTC GGGGCGATTG TTGGGTGCTT CGTCCGCTTC

101 TTCATTGTTC TCAACATTCT AGCTGCTCTT GCTGCATTGG CTCTGGAATT CTGTAGAGA TATTACTTGT CCTTCCAGGC TGTTCTTTCT GTAGCTCCCT
AAGTAACAAG AGTTGTAAGA TCGACGAGAA CGACGTAAAC GAGACCTTAA GAACATCTCT ATAATGAACA GGAAGGTCCG ACAAGAAAGA CATCGAGGGA

201 TGTTTTCTTT TTGTGATCAT GTTGCAGATG GCTGGGCAGT GCTCCCAAAA TGAATATTTT GACAGTTTGT TGCATGCTTG CATACTTGT CAACTTCGAT
ACAAAAGAAA AACACTAGTA CAACGTCTAC CGACCCGTCA CGAGGGTTTT ACTTATAAAA CTGTCAAAAC ACGTACGAAC GTATGGAACA GTTGAAGCTA
1 Me tLeuGlnMet AlaGlyGlnC ysSerGlnAs nGluTyrPhe AspSerLeuL euHisAlaCy sIleProCys GlnLeuArgC

301 GTTCTTCTAA TACTCCTCCT CTAACATGTC AGCGTTATTG TAATGCAAGT GTGACCAATT CAGTGAAAGG AACGAATGCG ATTCTCTGGA CCTGTTTGGG
CAAGAAGATT ATGAGGAGGA GATTGTACAG TCGCAATAAC ATTACGTTCA CACTGTTTCC TTCCTTACGC TAAGAGACCT GGACAAACCC

29 ysSerSerAs nThrProPro LeuThrCysG l nArgTyrCy sAsnAlaSer ValThrAsnS erValLysG l yThrAsnAla lIleuTrpT hrCysLeuG l

401 ACTGAGCTTA ATAATTTCTT TGGCAGTTTT CGTGCTAATG TTTTGTGCTAA GGAAGATAAG CTCTGAACCA TTAAAGGACG AGTTTAAAAA CACAGGATCA
TGACTCGAAT TATTAAAGAA ACCGTCAAAA GCACGATTAC AAAAACGATT CCTTCTATTC GAGACTTGGT AATTTCCTGC TCAAATTTTT GTGTCTCTAGT

62 yLeuSerfëu lIleIleSerL euAlaValPh eValLeuMet PheLeuLeuA rgLysIleSe rSerGluPro LeuLysAspG luPheLysAs nThrGlySer

501 GGTCTCCTGG GCATGGCTAA CATGACCTG GAAAAGAGCA GGACTGGTGA TGAATTTATT CTTCCGAGAG GCCTCGAGTA CACGGTGGAA GAATGCACCT
CCAGAGGACC CGTACCGATT GTAACTGGAC CTTTCTCTCGT CCTGACCACT ACTTAAATAA GAAGGCTCTC CGGAGCTCAT GTGCCACCTT CTTACGTGGA

95 GlyLeuLeuG lyMetAlaAs nIleAspLeu GluLysSera rgThrGlyAs pGluIleIle LeuProArgG lyLeuGluTy rThrValGlu GluCysThrC

601 GTGAAGACTG CATCAAGAGC AAACCGAAGG TCGACTCTGA CCATTGCTTT CCACTCCCAG CTATGGAGGA AGCGCAACC ATTCTTGTC A CACGAAAAAC
CACTTCTGAC GTAGTTCTCG TTTGGCTTCC AGCTGAGACT GGTAACGAAA GGTGAGGGTC GATACCTCCT TCCGCGTTGG TAAGAACAGT GGTGCTTTTG

129 ysGluAspCy sIleLysSer LysProLysV alAspSerAs pHisCysPhe ProLeuProA laMetGluG l uGlyAlaThr lIleLeuValT hrThrLysTh

701 GAATGACTAT TGCAAGAGCC TGCCAGCTGC TTTGAGTGCT ACGGAGATAG AGAAATCAAT TTCTGCTAGG TAATTAACCA TTTCGACTCG AGCAGTGCCA
CTTACTGATA ACGTTCTCGG ACGGTCGACG AAACCTCACGA TGCCTCTATC TCTTTAGTTA AAGACGATCC ATTAATTGTT AAAGCTGAGC TCGTCACGGT

162 rAsnAspTyr CysLysSerL euProAlaAl aLeuSerAla ThrGluIleG luLysSerIl eSerAlaArg OC*

801 CTTTAAAAAT CTTTGTGTCAG AATAGATGAT GTGTCAGATC TCTTTAGGAT GACTGTATTT TTCAGTTGCC GATACAGCTT TTTGTCTCTCT AACTGTGGAA
GAAATTTTTA GAAAACAGTC TTATCTACTA CACAGTCTAG AGAAATCCTA CTGACATAAA AAGTCAACGG CTATGTGCGA AAACAGGAGA TTGACACCTT

901 ACTCTTTATG TTAGATATAT TTCTCTAGGT TACTGTGGG AGCTTAATGG TAGAACTTC CTTGGTTTCA TGATTAAAGT CTTTTTTTTT CCTGA
TGAGAAAATAC AATCTATATA AAGAGATCCA ATGACAACCC TCGAATTACC ATCTTTGAAG GAACCAAGT ACTAATTTC AAAAAA AAAA GGA

FIG. 2

USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 4 of 29



1 ATGGATGACT CCACAGAAAG GGAGCAGTCA GCGCTTACTT CTGCGCTTAA GAAAGAGAA GAAATGAAAC TGAAGGAGTG TGTTTCCATC CTCCCACGGA
TACCTACTGA GGTGTCTTTC CCTCGTCAGT GCGGAATGAA GAACGGAATT CTTTCTCTT CTTTACTTTG ACTTCCTCAC ACAAGGAGTAG GAGGGTGCCT
1 M D D S T E R E Q S R L T S C L K K R E E M K L K E C V S I L P R K
101 AGGAAAGCCC CTCTGTCCGA TCCTCCAAAG ACGGAAAGCT GCTGGCTGCA ACCTTGCTGC TGGCACTGCT GTCTTGCTGC CTCACGGTGG TGTCTTTCTA
TCCTTTCCGG GAGACAGGCT AGGAGTTTC TGCCTTTCGA CGACCGACGT TGAACGACG ACCGTGACGA CAGAACGACG GAGTGCCACC ACAGAAAGAT
35 E S P S V R S S K D G K L L A A T L L L A L L S C C L T V V S F Y
201 CCAGGTGGCC GCCCTGCAAG GGGACCTGGC CAGCCTCCGG GCAGAGCTGC AGGGCCACCA CGCGGAGAAG CTGCCAGCAG GAGCAGGAGC CCCCRAAGGCC
GGTCCACCGG CGGACGTTTC CCCTGGACCG GTCGGAGGCC CGTCTCGACG TCCCGGTGGT GCGCCTCTTC GACGGTCTGC CTCGTCTCTCG GGGTTCCGG
68 Q V A A L Q G D L A S L R A E L Q G H H A E K L P A G A G A P K A
301 GGCTTGAGG AAGCTCCAGC TGTACCGCG GGAAGTAAAC TCCTTGAACC ACCAGCTCCA GGAGAAGGCA ACTCCAGTCA GAACAGCAGA AATAAGCGTG
CCGAACCTCC TTCGAGGTGC ACAGTGGCG CCTGACTTTT AGAACTTGG TGGTCGAGGT CCTCTTCCGT TGAGGTCTGT CTTGTCTGT TATTTCGCAC
101 G L E E A P A V T A G L K I F E P P A P G E G N S S Q N S R N K R A
401 CCGTTGAGG TCCAGAGAA ACAGTCACTC AAGACTGCTT GCAACTGATT GCAGACAGTG AAACACCAAC TATACAAAAA GGATCTTACA CATTTGTTCC
GGCAAGTCCC AGGTCTTCTT TGTCAGTGAG TTCTGACGAA CGTTGACTAA CGTCTGTCTC TTTGTGGTTG ATATGTTTTT CCTAGAATGT GTAACAAGG
135 V Q G P E E T V T Q D C L Q L I A D S E T P T I Q K G S Y T F V P
501 ATGGCTTCTC AGCTTTAAAA GGGGAAGTGC CCTAGAAGAA AAAGAGAATA AAATATTGGT CAAAGAAACT GGTACTTTT TTATATATGG TCAGTTTAA
TACCGAAGAG TCGAAATTTT CCCCTTCACG GGATCTTCTT TTTCTCTTAT TTTATAACCA GTTCTTTGA CCAATGAAAA AATATATACC AGTCCAAAT
168 W L L S F K R G S A L E E K E N K I L V K E T G Y F F I Y G Q V L
601 TATACTGATA AGACCTACGC CATGGGACAT CTAATTCAGA GGAAGAAGGT CCATGTCTTT GGGGATGAAT TGAGTCTGGT GACTTTGTTT CGATGTATTC
ATATGACTAT TCTGGATCG GTACCCCTGTA GATTAAGTCT CCTTCTTCCA GTTACAGAAA CCCCTACTTA ACTCAGACCA CTGAAAACAA GCTACATAAG
201 Y T D K T Y A M G H L I Q R K K V H V F G D E L S L V T L F R C I Q
701 AAAATATGCC TGAACACTA CCCAATAATT CCTGCTATTC AGCTGGCATT GCAAAACTGG AAGRAGGAGA TGAACCTCAA CTTGCAATAC CAAGAGAAAA
TTTTATACGG ACTTTGTGAT GGGTTATTAA GGACGATAAG TCGACCGTAA CGTTTGGACC TTCTTCTCTT ACTTGAGGT GAACGTTATG GTTCTCTTTT
235 N M P E T L P N N S C Y S A G I A K L E E G D E L Q L A I P R E N
801 TGCACAAATA TCACTGGATG GAGATGTCAC ATTTTGTGGT GCATTGAAAC TGCTGTGA
ACGTGTTTAT AGTGACCTAC CTCTACAGTG TAAAAACCA CGTAACCTTG ACGACACT
268 A Q I S L D G D V T F F G A L K L L O

FIG. 3



USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 5 of 29

1 GGACGAGGC TTCCTAGAGG GACTGGAACC TAATTCTCCT GAGGCTGAGG GAGGTGGAG GGTCTCAAGG CAACGCTGGC CCCACGACGG AGTGCCAGGA
CCATGCTCCG AAGGATCTCC CTGACCTTGG ATTAAGAGGA CTCCGACTCC CTCCACCTC CCAGAGTTCC GTTGGCACC GGTGCTGCC TCACGGTCTCT
101 GCACTAACAG TACCCTTAGC TTGCTTTTCTCCT CCTCCCTCCT TTTTATTTTC AAGTTCCCTT TTATTCTCTC TTGCGTAACA ACCTTCTTCC CTTCTGCACC
CGTGATTGTC ATGGGAATCG AACGAAAGGA GGAGGGAGGA AAAATAAAAG TTCAAGGAAA AATAAAGAGG AACGCATTGT TGAAGAAGG GAAGACGTGG
201 ACTGCCCCGTA CCCTTACCCG CCCCAGCCACC TCCTTGCTAC CCACTCTTG AAACACAGC TGTGGCAGG GTCCCCAGCT CATGCCAGCC TCATCTCCTT
TGACGGGCAT GGAATGGC GGGCGGTGG AGGAACGATG GGTGAGAAC TTTGGTGTG ACAACCGTCC CAGGGGTCCA GTACGGTCCG AGTAGAGGAA
M P A S S P F
301 TCTTGCTAGC CCCAAAGG CCTCCAGGCA ACATGGGGG CCTCCAGGCA GAGCTCAGA GAGCGGCAC TCTCAGTTGC CCTCTGGTTG AGTTGGGGG CAGCTCTGGG
AGACGATCG GGGTTTCCC GGAGGTCCGT TGTACCCCC TGTACCTCTT GGTACCTCTT GGTACCTCTT GGTACCTCTT GGTACCTCTT GGTACCTCTT
8 L L A P K G P P G N M G G P V R E P A L S V A L W L S W G A A L G
401 GGCGGTGGCT TGTGCCATGG CTCTGCTGAC CCAACAAACA GAGCTGCAGA GCCTCAGGAG AGAGGTGAGC CGGTGCAGG GGACAGGAGG CCCCCTCCAG
CCGGCACCGA ACACGGTACC CGTCTCAGAG GGCCTCGTCT CAAGGCTACG GGACCTTCGG ACCCTCTTAC CCCTCTCTAG GGCCTTTTCC TCTCGTCACG
41 A V A C A M A L L T Q Q T E L Q S L R R E V S R L Q G T G G P S Q
501 AATGGGGAAG GGTATCCCTG GCAGAGTCTC CCGAGGAGCA GTTCCGATGC CCTGGAAGCC TGGGAGAATG GGGAGAGATC CTCCGATGT ACAGAGGTGA TGTGGCAACC
TTACCCCTTC CCATAGGGAC CGTCTCAGAG GGCCTCGTCT CAAGGCTACG GGACCTTCGG ACCCTCTTAC CCCTCTCTAG GGCCTTTTCC TCTCGTCACG
74 N G E G Y P W Q S L P E Q S S D A L E A W E N G E R S R K R R A V L
601 TCACCCAAA ACAGAAGAAG CAGCACTCTG TCCTGCACCT GGTTCCTTTC CCTGGAAGCC TGGGAGAATG GGGAGAGATC CTCCGATGT ACAGAGGTGA TGTGGCAACC
AGTGGGTTT TGTCTTCTC GTCTGAGAC AGGACGTGGA CCAAGGGTAA TTGCGGTGGA GGTTCCTACT GAGGTACAC TGTCTCCACT ACACCGTTGG
108 T Q K Q K K Q H S V L H L V P I N A T S K D D S D V T E V M W Q P
701 AGCTCTTAGG CGTGGGAGAG GCCTACAGGC CCAAGGATAT GGTGTCCGAA TCCAGGATGC TGGAGTTTAT CTGCTGTATA GCCAGGTCTT GTTCAAGAC
TCGAGAATCC GCACCCCTCTC CGGATGTCCG GGTTCCTATA CCACAGGCTT AGGTCTTACG ACCTCAAATA GACGACATAT CGGTCCAGGA CAAAGTTCTG
141 A L R R G R G L Q A Q G Y G V R I Q D A G V Y L L Y S Q V L F Q D
801 GTGACTTTCA CCATGGGTCA GGTGGTGTCT CGAGAGGCC AAGGAAGCA GGAGACTCTA TTCCGATGA TAAGAAGTAT GCCCTCCAC CCGACCGGG
CACTGAAAGT GGTACCCAGT CCACCACAGA GCTCTTCCG GTTCTTCCG TTTCTTCCG TTTCTTCCG TTTCTTCCG TTTCTTCCG TTTCTTCCG
174 V T F T M G Q V V S R E G Q G R Q E T L F R C I R S M P S H P D R A
901 CCTACAACAG CTGCTATAGC GCAGGTGTCT TCCATTACA CCAAGGGGAT ATTCTGAGTG TCATAATTCC CCGGCAAGG GCGAAACTTA ACCTCTCTCC
GGATGTTGTC GACGATATCG CGTCCACAGA AGGTAATGT GGTTCCTTCCG TTAAGACTCAC AGTATTAGG GGGCCGTTC CGCTTTGAAT TGGAGAGAGG
208 Y N S C Y S A G V F H L H Q G D I L S V I I P R A R A K L N L S P

FIG. 4A



1001 ACATGGAACC TTCCTGGGGT TTGTGAACT GTGATTGTGT TATAAAAAGT GGCTCCCAGC TTGGAAGACC AGGGTGGGTA CATACTGGAG ACAGCCAAGA
TGTAACCTTGG AAGGACCCCA AACACTTTGA CACTAACACA ATATTTTCA CCGAGGGTCG AACCTTCTGG TCCCACCCAT GTATGACCTC TGTCGGTTCT
241 H G T F L G F V K L O
1101 GCTGAGTATA TAAAGGAGAG GGAATGTGCA GGAACAGAGG CATCTTCCTG GGTTTGGCTC CCCGTTCCCT ACTTTTCCCT TTTCATTCCC ACCCCCTAGA
CGACTCATAT ATTTCCCTCTC CCTTACACGT CCTTGTCTCC GTAGAAGGAC CCAACCCGAG GGGCAAGGAG TGAAGAGGGA AAAGTAAGGG TGGGGGATCT
1201 CTTTGATTTT ACGGATATCT TGCTTCTGTT CCCCATGGAG CTCCGAATTC TTGCGTGTGT GTAGATGAGG GGGCGGGGAC GGGCGCCAGG CATGTTCAG
GAAACTAAAA TGCCTATAGA ACGAAGACAA GGGGTACCTC GAGGCTTAAG AACGCACACA CATCTACTCC CCGCCCCCTG CCGCGGTCC GTAACAAGTC
1301 ACCTGGTCGG GGCCCACTGG AAGCATCCAG AACAGCACCA CCATCTTA
TGGACCAGCC CCGGGTGACC TTCGTAGGTC TTGTCGTGGT GGTAGAAT

FIG. 4B



PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXYYYYYYY	(Length = 12 amino acids)

% amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

5 divided by 15 = 33.3%

FIG. 5A

PRO	XXXXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXXYYYYYYZZYZ	(Length = 15 amino acids)

% amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

5 divided by 10 = 50%

FIG. 5B



htACI(265) htACI	M S G L G R S R R G G R S R V D Q E E R F P Q G L W T G V A M R S C P E E Q Y W D P L L G T C M S C M S G L G R S R R G G R S R V D Q E E R F P Q G L W T G V A M R S C P E E Q Y W D P L L G T C M S C	1020304050
htACI(265) htACI	K T I C N H Q S Q R T C A A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G G Q H P K Q C K T I C N H Q S Q R T C A A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G G Q H P K Q C	60708090100
htACI(265) htACI	A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N S D N S G R Y Q G L E H R G S E A S P A L A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N S D N S G R Y Q G L E H R G S E A S P A L	110120130140150
htACI(265) htACI	P G L K L S A D Q V A L V Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q P R S R P G L K L S A D Q V A L V Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q P R S R	160170180190200
htACI(265) htACI	P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T C S F C F P E C R A P T Q E S A V T P G T P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T C S F C F P E C R A P T Q E S A V T P G T	210220230240250
htACI(265) htACI	P D P T C A G R T W G C H T R T T V L Q P C P H I P D S G L G I V C V A P P R E G - - - - Z P D P T C A G R W G C H T R T T V L Q P C P H I P D S G L G I V C V A P P R E G - - - - Z	260270280290300

FIG. 6




FIG. 7

FIG. 8A







FIG. 8B



Ip:with protein A
WB with α Flag HR

FIG. 8C

FIG. 8D





FIG. 8F

FIG. 8E






FIG. 8G




FIG. 8H

FIG. 9A

Blys/
TALL-1





FIG. 9B

TACI

BCMA

Vector







FIG. 10






FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A

13146 U.S. PTO
120203




FIG. 13B




FIG. 14A



Summary of anti-April mABs

mAb	Isotype	Epitope	Binding (ELISA) April	TALL	Block April binding to BCMA	TACI
3C6.4.2	IgG2a	C	++	-	+++	+
5E8.7.4	IgG2a	A	++	-	-	-
5E11.1.2	IgG1	C?	++	-	+	+
5G8.2.2	IgG2a	B	++	-	-	-

MAb 5E11.1.2 may bind to the similar epitope.

FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B



FIG. 17C



FIG. 17D



FIG. 17A



FIG. 17B

13146 U.S. PTO
120203




FIG. 17E



FIG. 17F




FIG. 18C




FIG. 18B




FIG. 18A




FIG. 18E




FIG. 18D




FIG. 19B




FIG. 19A



TACI-Fc treatment of mice inhibits EAE in MBP-TCR transgenic mice

